Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of SYNACT.ST is 35 and suggests 88% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell